Pharmacists Perspective

• Key Data in Non-Hodgkin Lymphoma From EHA 2023   Key data in non-Hodgkin lymphoma from EHA 2023 include evidence for omitting radiotherapy, findings of no benefit of IV over IT methotrexate in CNS prophylaxis, and two positive CAR T-cell studies.
  Medscape, July 03, 2023
• Clinical Updates in Myelofibrosis From EHA 2023   Novel strategies in ruxolitinib-refractory patients, use of BET inhibitors plus JAK inhibitors to deepen response, and luspatercept to tackle anemia are covered in myelofibrosis updates from EHA 2023.
  Medscape, June 30, 2023
• 3 Years Into Long COVID: Where Do We Go From Here? In April 2021, after 13 months of having long COVID and helping conduct two patient-led research studies on the condition, I testified to Congress about what was needed to address the crisis.
  Medscape Infectious Diseases, June 29, 2023
• Highlights on Thrombosis and Hemostasis From EHA 2023   Thrombosis and hemostasis highlights from EHA 2023 identify VTE as a major complication in acute promyelocytic leukemia, biomarkers for VTE in lung cancer, and an investigational thrombosis inhibitor.
  Medscape, June 29, 2023
• Bempedoic Acid: A Statin-Intolerance Savior? Associated with positive cardiovascular outcomes in a mixed cardiovascular risk population, bempedoic is an evidenced-based alternative for statin-intolerant patients.
  Medscape Diabetes & Endocrinology, June 29, 2023
• At ASCO, the Cancer Community Hyped the Wrong Trial Oncologist Bishal Gyawali, MD, PhD, highlights concerns surrounding which trials the oncology community is choosing to celebrate.
  Medscape Oncology, June 29, 2023
• Episode 2: Evolving Research in the Field of Chronic Myeloid Leukemia   Drs Michael J. Mauro and Ehab Atallah discuss current chronic myeloid leukemia research, where the US stands in comparison with the world, and the important work being conducted by the Cure CML Consortium.
  Medscape, June 29, 2023
• Episode 1: Chronic Myeloid Leukemia Therapy and the Mark Cuban Effect   Drs Michael J. Mauro and Hagop Kantarjian discuss the cost of chronic myeloid leukemia therapy, long-term safety, adverse events, and the financial toxicity to the patient and the healthcare system.
  Medscape, June 29, 2023
• Tirzepatide: Therapeutic Titan or Costly Cure? Tirzepatide has been boldly positioned as a third-generation obesity medication. But what is its role in primary care, and more important, can we afford it?
  Medscape Diabetes & Endocrinology, June 28, 2023
• Effectiveness of Newer Biologics in a Patient With Psoriasis and Worsening PsA Symptoms   Experts discuss treatment options for a patient with moderate to severe plaque psoriasis and worsening psoriatic arthritis symptoms, including an Achilles tendon insertion and back pain.
  Medscape, June 28, 2023
• Endocrine Therapy Plus Targeted Agents in MBC Endocrine therapy remains the mainstay of treatment in metastatic breast cancer. Dr Erica Mayer discusses adding targeted agents as clinicians strive to improve therapeutic options and efficacy.
  Medscape Oncology, June 28, 2023
• S2 Episode 4: Oral Psoriasis Drugs: What Are NPs Prescribing?   Dr Steven R. Feldman and nurse practitioner Lakshi M. Aldredge discuss systemic therapy for psoriasis and how nurse practitioners and physician associates fill an important gap.
  Medscape, June 28, 2023
• Key Abstracts in Early Breast Cancer From ASCO 2023   Dr Harold Burstein highlights abstracts in early breast cancer from ASCO 2023, including the NATALEE trial of CDK4/6 inhibitor ribociclib and a meta-analysis on risk reduction with ovarian ablation.
  Medscape, June 27, 2023
• Key Abstracts in Metastatic Breast Cancer From ASCO 2023   Dr Harold Burstein highlights abstracts in metastatic breast cancer from ASCO 2023, including data on antibody-drug conjugates from the TROPiCS-02 trial update, and phase 2 data on the novel HER3-DXd.
  Medscape, June 27, 2023
• Key Data in Endometrial Cancer From ASCO 2023   Top abstracts in endometrial cancer from ASCO 2023 include patient-reported outcomes in the RUBY trial, genetic testing referral rates, and the impact of MMR deficiency on immunotherapy responses.
  Medscape, June 27, 2023
• Highlights in Renal Cell Carcinoma From ASCO 2023   Data on combination therapies, real-world findings on TKIs, and 4-year follow-up of the CLEAR study are among the highlights in renal cell carcinoma from ASCO 2023, as reported by Dr Eric Jonasch.
  Medscape, June 27, 2023
• Key Data on Advanced NSCLC From ASCO 2023   Data from KEYNOTE-789, plus results on the EGFR exon 20 inhibitor sunvozertinib and a promising sotorasib combination for KRAS G12C-mutant disease, are highlights in advanced NSCLC from ASCO 2023.
  Medscape, June 27, 2023
• Dyslipidemia: What Would You Do? Dr Charles Vega asks readers to comment on his management plan for a patient with an unsatisfactory lipid profile.
  Medscape Family Medicine, June 27, 2023
• Episode 4: Psychosocial and Psychological Adjustment in Cancer Survivorship   Drs Ann H. Partridge and Donald L. Rosenstein discuss psychosocial and psychological adjustments to a cancer diagnosis, treatment, and living with and beyond cancer in survivorship, including anxiety, grief, and suicidal ideation.
  Medscape, June 27, 2023
• Is Low Testosterone the Cause of Declining Sexual Function? It's common to think that testosterone replacement is the only cure for low libido in postmenopausal women, but it's more complicated. Other hormones can contribute to an unpleasant sexual experience.
  Medscape Diabetes & Endocrinology, June 26, 2023